Cartesian Therapeutics (RNAC) Non-Current Deferred Tax Liability (2022 - 2026)

Cartesian Therapeutics (RNAC) has 5 years of Non-Current Deferred Tax Liability data on file, last reported at $6.9 million in Q1 2026.

• Non-Current Deferred Tax Liability for Q1 2026 came in at $6.9 million, down 56.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.9 million (down 56.95% YoY), and the FY2025 annual result was $6.9 million, down 56.95% from the prior year.
• Non-Current Deferred Tax Liability steadied at $6.9 million in Q1 2026 per RNAC's latest filing, from $6.9 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $44.0 million in Q4 2023 and troughed at $3.3 million in Q4 2022.
• A 5-year average of $15.8 million and a median of $15.9 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability jumped 1252.47% in 2023, then plunged 63.34% in 2024.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $3.3 million in 2022, then jumped by 1252.47% to $44.0 million in 2023, then sank by 63.34% to $16.1 million in 2024, then sank by 56.95% to $6.9 million in 2025, then changed by 0.0% to $6.9 million in 2026.
• Business Quant data shows RNAC's Non-Current Deferred Tax Liability at $6.9 million in Q1 2026, $6.9 million in Q4 2025, and $16.1 million in Q3 2025.